Doxorubicin is available as a powder for injection or as a liquid solution [2 mg/mL] administered intravenously (IV) via a central line as a continuous infusion.

**Adult Dosing**

- 60 to 75 mg/m^2 intravenously (IV) every 21 days OR

- 60 mg/m2 IV every 14 days OR

- 40 to 60 mg/m^2 IV every 21 to 28 days OR

- 20 mg/m^2/dose once/week

**Pediatric Dosing**

- 35 to 75 mg/m^2 intravenously (IV) every 21 days

- 20 to 30 mg/m^2/dose once/week

- 60 to 90 mg/m^2 IV over 96 hours every 3 to 4 weeks

**Renal Impairment**

- No dosage adjustment is necessary

**Hepatic Impairment**

- Total serum bilirubin less than 1.2 mg/dL: No dosage adjustment is necessary

- Total serum bilirubin 1.2 to 3.0 mg/dL: Decrease dose by 50%

- Total serum bilirubin: 3.1 to 5.0 mg/dL: Decrease dose by 25%

- Severe hepatic impairment: Contraindicated due to toxicity

Due to the side effect profile and toxicity of doxorubicin, patients are only allowed a lifetime dose of 550 mg/m^2. Patients receiving doxorubicin therapy must receive close follow-up and monitoring of blood counts, liver function, and heart function studies.